Drug Profile
AG 014
Alternative Names: AG014; Certolizumab - Precigen Inc; Lactococcus lactis expressing certolizumab; Lactococcus lactis secreting certolizumabLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator ActoGeniX
- Developer Precigen Inc
- Class Anti-inflammatories; Bacteria; Fab fragments
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in Belgium (PO, Capsule)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 05 Oct 2018 Phase I development is ongoing (Intrexon pipeline, October 2018)